July 3, 2024
Amsterdam, the Netherlands - Royal Philips (http://www.philips.com/newscenter)
(NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced
the appointment of Ms Ling Liu as the Chief Region Leader of Philips Greater
China, effective immediately. Ms Liu is now a member of Philips' Executive
Committee, reporting to Philips CEO Roy Jakobs. She succeeds Andy Ho, who has
decided to retire after a long and successful career. Ms Liu and Mr Ho continue
to work together to ensure a smooth handover.
"Ling is a talented, trusted leader and I am delighted that she will join
Philips' Executive Committee as the Chief Region Leader of Philips Greater
China," said Roy Jakobs, CEO of Royal Philips. "She is a proven executive who
brings a wealth of international experience and deep HealthTech expertise in
China. I would also like to express my deep gratitude to Andy for his
exceptional leadership in delivering on our commitment to supporting China's
national health strategy and becoming a trusted partner for professional
customers as well as individual consumers. At the same time as driving sustained
financial and operational performance over the last nine years."
Ms Liu joined Philips in 1998 and has held multiple roles across the business,
living and working in Greater China, the Netherlands and North America. Most
recently, she was Chief Commercial Officer in Greater China, following her role
as Head of Finance for Philips in North America. She has a track record of
driving execution and boosting performance, developing teams and delivering
outstanding value to customers and partners. She is passionate about delivering
quality care and contributing to sustainable healthcare in China.
Ms Liu holds a master of finance and control from Maastricht University, a
master's degree in management engineering from Shanghai University, and a
bachelor's degree in physics from Zhejiang University.
2023 marked the 100th anniversary of Philips in China, an achievement that
stands as a testament to Philips' commitment and dedication to improving
people's lives through meaningful innovation and fostering strong partnerships
in China. With sustained growth and being Philips' second largest market, it has
been one of the major growth engines for the company. Philips China is focused
on supporting China's national health strategy, supplying hospitals with
solutions for their clinical and research needs, and empowering consumers to
manage their health and well-being. With the aim of better serving the Chinese
market, Philips is committed to its 'In China, For China' strategy, which
focuses on local innovation, manufacturing, services and partnership.
Additional information on Philips' Executive Committee can be found here
(https://www.philips.com/a-w/about/executive-committee.html).
For further information, please contact:
Ben Zwirs
Philips External Relations
Tel.: +31 6 1521 3446
E-mail: ben.zwirs@philips.com (mailto:ben.zwirs@philips.com)
Dorin Danu
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: dorin.danu@philips.com (mailto:dorin.danu@philips.com)
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company
focused on improving people's health and well-being through meaningful
innovation. Philips' patient- and people-centric innovation leverages advanced
technology and deep clinical and consumer insights to deliver personal health
solutions for consumers and professional health solutions for healthcare
providers and their patients in the hospital and the home. Headquartered in the
Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-
guided therapy, monitoring and enterprise informatics, as well as in personal
health. Philips generated 2023 sales of EUR 18.2 billion and employs
approximately 69,100 employees with sales and services in more than 100
countries. News about Philips can be found at www.philips.com/newscenter
(https://www.philips.com/a-w/about/news/home.html).
Forward-looking statements
This release contains certain forward-looking statements with respect to the
financial condition, results of operations and business of Philips and certain
of the plans and objectives of Philips with respect to these items. Examples of
forward-looking statements include statements made about the strategy, estimates
of sales growth, future EBITA, future developments in Philips' organic business
and the completion of acquisitions and divestments. By their nature, these
statements involve risk and uncertainty because they relate to future events and
circumstances and there are many factors that could cause actual results and
developments to differ materially from those expressed or implied by these
statements.
Â